Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Differential expression and correlation analysis of whole transcriptome for type 2 diabetes mellitus

Liu F., Peng A., Zhu X., Wang G.

Prospective Study on Type 2 Diabetes, Immune Modulation, published in Front Endocrinol (Lausanne) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Front Endocrinol (Lausanne) (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40951426
PMCID
PMC12425763
DOI
10.3389/fendo.2025.1541261

Abstract (original English)

Background Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease that accounts for 90% or more of all diabetes cases and contributes to the global public health burden. The pathogenesis of T2DM is extremely complex, and increasing evidence suggests that non-coding RNA (ncRNA) is an important molecule involved in the regulation of T2DM. However, there are still many unknown lncRNAs and circRNAs that need further exploration. This study aims to explore new lncRNAs and circRNAs and their potential biological functions in T2DM. Methods This study utilized high-throughput whole-transcriptome RNA sequencing technology to sequence and analyze five whole blood samples from each group, identifying differentially expressed mRNAs, lncRNAs, circRNAs, and miRNAs between the T2DM group and the control group. The biological functions of the differentially expressed RNAs were analyzed using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Subsequent association analysis was performed based on the screened differentially expressed mRNA, lncRNA, circRNA, and miRNA to construct a competitive endogenous RNA (ceRNA) network. Results Differential expression results showed that 411 mRNAs were differentially expressed, 500 lncRNAs were differentially expressed, 356 circRNAs were differentially expressed, and 67 miRNAs were differentially expressed in

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansDiabetes Mellitus, Type 2MicroRNAsRNA, MessengerCase-Control StudiesGene Expression ProfilingGene Expression RegulationMiddle AgedFemaleMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research